The University of Chicago Header Logo

Connection

Michael H. Davidson to Ezetimibe

Back to Details
This is a "connection" page, showing publications Michael H. Davidson has written about Ezetimibe.
Michael H. Davidson
Connection Strength
2.469
Ezetimibe
  1. Role of Ezetimibe in Lipid-Lowering and Cardiovascular Disease Prevention. Curr Atheroscler Rep. 2015 Dec; 17(12):72.
    View in: PubMed
    Score: 0.546
  2. Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments. Curr Atheroscler Rep. 2024 Feb; 26(2):35-44.
    View in: PubMed
    Score: 0.239
  3. Comparing remnant lipoprotein cholesterol measurement methods to evaluate efficacy of ezetimibe/statin vs statin therapy. J Clin Lipidol. 2019 Nov - Dec; 13(6):997-1007.e8.
    View in: PubMed
    Score: 0.177
  4. Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans. Atherosclerosis. 2013 Oct; 230(2):322-9.
    View in: PubMed
    Score: 0.116
  5. The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients. Clin Ther. 2013 Aug; 35(8):1247-52.
    View in: PubMed
    Score: 0.116
  6. Therapies targeting exogenous cholesterol uptake: new insights and controversies. Curr Atheroscler Rep. 2011 Feb; 13(1):95-100.
    View in: PubMed
    Score: 0.098
  7. Statin and ezetimibe combination therapy in cardiovascular disease. Curr Opin Endocrinol Diabetes Obes. 2009 Apr; 16(2):183-8.
    View in: PubMed
    Score: 0.086
  8. Novel nonstatin strategies to lower low-density lipoprotein cholesterol. Curr Atheroscler Rep. 2009 Jan; 11(1):67-70.
    View in: PubMed
    Score: 0.085
  9. Is it over for ezetimibe? Expert Rev Cardiovasc Ther. 2008 Jul; 6(6):781-3.
    View in: PubMed
    Score: 0.082
  10. Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications. Cleve Clin J Med. 2008 Jul; 75(7):479-82, 486-8, 490-1.
    View in: PubMed
    Score: 0.082
  11. Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Rev Cardiovasc Ther. 2006 Jul; 4(4):461-76.
    View in: PubMed
    Score: 0.071
  12. Cholesterol absorption blockade with ezetimibe. Curr Drug Targets Cardiovasc Haematol Disord. 2005 Dec; 5(6):455-62.
    View in: PubMed
    Score: 0.068
  13. Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin Pharmacother. 2005 Jan; 6(1):131-9.
    View in: PubMed
    Score: 0.064
  14. Combination therapy in the management of complex dyslipidemias. Curr Opin Lipidol. 2004 Aug; 15(4):423-31.
    View in: PubMed
    Score: 0.062
  15. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract. 2004 Aug; 58(8):746-55.
    View in: PubMed
    Score: 0.062
  16. Newer pharmaceutical agents to treat lipid disorders. Curr Cardiol Rep. 2003 Nov; 5(6):463-9.
    View in: PubMed
    Score: 0.059
  17. Efficacy of simvastatin and ezetimibe in treating hypercholesterolemia. J Am Coll Cardiol. 2003 Jul 16; 42(2):398-9; author reply 399.
    View in: PubMed
    Score: 0.058
  18. Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial. J Clin Lipidol. 2023 Jul-Aug; 17(4):491-503.
    View in: PubMed
    Score: 0.057
  19. Ezetimibe: a novel option for lowering cholesterol. Expert Rev Cardiovasc Ther. 2003 May; 1(1):11-21.
    View in: PubMed
    Score: 0.057
  20. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002 Dec 18; 40(12):2125-34.
    View in: PubMed
    Score: 0.056
  21. Combination therapy for dyslipidemia: safety and regulatory considerations. Am J Cardiol. 2002 Nov 20; 90(10B):50K-60K.
    View in: PubMed
    Score: 0.055
  22. Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials. J Am Heart Assoc. 2018 09 18; 7(18):e009221.
    View in: PubMed
    Score: 0.041
  23. Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control. Circulation. 2016 Dec 13; 134(24):1931-1943.
    View in: PubMed
    Score: 0.036
  24. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res. 2012 Oct; 51(4):314-24.
    View in: PubMed
    Score: 0.027
  25. Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction. J Clin Lipidol. 2012 Mar-Apr; 6(2):180-91.
    View in: PubMed
    Score: 0.026
  26. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am J Cardiol. 2011 Aug 15; 108(4):523-30.
    View in: PubMed
    Score: 0.025
  27. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials. Clin Ther. 2006 Jun; 28(6):849-59.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.